LCM
AVTX icon

Landscape Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Landscape Capital Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,337
Closed -$424K – 721
2025
Q3 		$424K Buy
+33,337
New +$287K 0.03% 482

Other funds holding AVTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Landscape Capital Management's AVTX Position: Q4 2025 in Review

Landscape Capital Management sold out of Avalo Therapeutics (AVTX) in Q4 2025, closing a stake of 33,337 shares — an estimated $424K sold.

Landscape Capital Management first reported a position in AVTX in Q3 2025 and held it in 1 quarter. The position peaked at $424K in Q3 2025. 84 funds tracked by Wall St. Rank hold AVTX as of Q4 2025.

  • Landscape Capital Management reported no remaining Avalo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Landscape Capital Management sold 33,337 Avalo Therapeutics shares in Q4 2025, an estimated $424K.
  • Landscape Capital Management first reported a position in Avalo Therapeutics in Q3 2025 and held it in 1 quarter.
  • Landscape Capital Management's Avalo Therapeutics position peaked at $424K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2025.

Based on Landscape Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.